Top Page
Jazz Pharmaceuticals
(NASDAQ:JAZZ)
Jazz Pharmaceuticals (JAZZ) vs. SPDR S&P 500 ETF (SPY)
Jazz Pharmaceuticals Business Overview & Revenue Model
Jazz Pharmaceuticals Key Performance Indicators (KPIs)
Highlights revenue generated from neuroscience products, indicating the company's strength and focus in treating neurological disorders, and potential growth in this specialized market.
The FlyJazz Pharmaceuticals Earnings Call Summary
Jazz Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.16B | 4.07B | 3.83B | 3.66B | 3.09B | 2.36B |
| Gross Profit | 3.55B | 3.62B | 3.40B | 3.12B | 2.65B | 2.21B |
| EBITDA | 257.52M | 1.52B | 1.45B | 1.47B | 1.03B | 1.04B |
| Net Income | -368.48M | 560.12M | 414.83M | -224.06M | -328.95M | 238.62M |
Balance Sheet | ||||||
| Total Assets | 11.36B | 12.01B | 11.39B | 10.84B | 12.30B | 6.54B |
| Cash, Cash Equivalents and Short-Term Investments | 2.05B | 2.99B | 1.63B | 881.48M | 591.45M | 2.13B |
| Total Debt | 5.43B | 6.16B | 5.79B | 5.81B | 6.15B | 2.25B |
| Total Liabilities | 7.40B | 7.92B | 7.66B | 7.75B | 8.33B | 2.88B |
| Stockholders Equity | 3.96B | 4.09B | 3.74B | 3.09B | 3.97B | 3.66B |
Cash Flow | ||||||
| Free Cash Flow | 1.34B | 1.35B | 1.07B | 773.78M | 732.98M | 520.39M |
| Operating Cash Flow | 1.39B | 1.40B | 1.09B | 1.27B | 778.51M | 899.65M |
| Investing Cash Flow | -1.33B | -508.19M | -163.06M | -446.23M | -5.21B | -1.01B |
| Financing Cash Flow | -957.10M | 20.52M | -305.25M | -529.49M | 3.97B | 528.07M |
Jazz Pharmaceuticals Technical Analysis
Jazz Pharmaceuticals Risk Analysis
Jazz Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $8.50B | 95.60 | 16.47% | ― | 17.92% | -26.13% | |
74 Outperform | $7.82B | 13.59 | 124.50% | ― | 31.19% | 59.01% | |
64 Neutral | $9.90B | 130.46 | 3.80% | 0.50% | 3.85% | -48.17% | |
63 Neutral | $10.13B | ― | -9.06% | ― | 4.14% | -179.96% | |
61 Neutral | $13.98B | ― | -14.73% | ― | -83.82% | -109.22% | |
52 Neutral | $14.56B | ― | -60.76% | ― | -100.00% | -44.24% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Jazz Pharmaceuticals Corporate Events
On November 17, 2025, Jazz Pharmaceuticals announced positive results from the Phase 3 HERIZON-GEA-01 trial, which evaluated Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. The trial demonstrated statistically significant improvements in progression-free survival and overall survival compared to the standard treatment, trastuzumab plus chemotherapy. These findings suggest that Ziihera could become the new standard of care for this patient group, and Jazz Pharmaceuticals plans to submit a supplemental Biologics License Application in the first half of 2026.
The most recent analyst rating on (JAZZ) stock is a Buy with a $230.00 price target. To see the full list of analyst forecasts on Jazz Pharmaceuticals stock, see the JAZZ Stock Forecast page.
Jazz Pharmaceuticals’ recent earnings call painted a picture of robust growth and strategic advancements, tempered by some challenges. The overall sentiment was positive, with the company celebrating record revenue achievements and multiple FDA approvals. However, concerns about future competition from generics and a decline in Zepzelca sales were also acknowledged.
Jazz Pharmaceuticals plc, a global biopharmaceutical company headquartered in Dublin, Ireland, focuses on developing life-changing medicines for serious diseases, with a diverse portfolio that includes therapies for sleep disorders, epilepsy, and oncology.
On October 23, 2025, Jazz Pharmaceuticals announced the appointment of Dr. Ted Love to its board of directors, effective December 1, 2025. Dr. Love will serve as a Class I director until the 2027 annual general meeting and will join the Audit and Science and Medicine Committees. Concurrently, Kenneth W. O’Keefe announced his retirement from the board, effective December 1, 2025, with no disputes influencing his decision.
The most recent analyst rating on (JAZZ) stock is a Buy with a $199.00 price target. To see the full list of analyst forecasts on Jazz Pharmaceuticals stock, see the JAZZ Stock Forecast page.
Jazz Pharmaceuticals is conducting a significant clinical study titled ‘ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.’ The study aims to evaluate whether ONC201 can improve overall survival and progression-free survival in patients with H3 K27M-mutant diffuse glioma post-radiotherapy. This research holds promise for advancing treatment options for this aggressive brain cancer.
Jazz Pharmaceuticals is conducting a Phase I study titled ‘A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms.’ The study aims to evaluate the safety and tolerability of ONC206, an oral drug, in patients with recurrent CNS neoplasms, focusing on determining the maximum-tolerated dose and identifying dose-limiting toxicities.
On October 21, 2025, Jazz Pharmaceuticals and its subsidiaries reached a global settlement agreement with Avadel Pharmaceuticals to resolve all disputes, including ongoing patent infringement litigation. As part of the settlement, Jazz will grant Avadel licenses for its Lumryz product, while Avadel will pay royalties to Jazz and refrain from marketing certain products until 2028. Jazz will pay Avadel $90 million and waive certain royalties, expecting a pre-tax charge of approximately $90 million in Q3 2025. The agreement aims to dismiss pending legal proceedings and includes mutual releases of claims.
The most recent analyst rating on (JAZZ) stock is a Buy with a $180.00 price target. To see the full list of analyst forecasts on Jazz Pharmaceuticals stock, see the JAZZ Stock Forecast page.
Jazz Pharmaceuticals has recently completed a clinical study titled ‘A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer.’ The study aimed to evaluate the safety and effectiveness of combining zanidatamab with evorpacept (ALX148) in treating patients with advanced HER2-expressing cancers. This study is significant as it explores new treatment avenues for cancers that express the HER2 protein, potentially offering new hope for patients with limited options.
Jazz Pharmaceuticals recently updated its Phase 2 clinical study on ZW25 (zanidatamab) combined with chemotherapy for HER2-expressing gastrointestinal cancers. The study aims to assess the safety and efficacy of this treatment in patients with gastroesophageal adenocarcinoma, biliary tract cancer, and colorectal cancer. This research is significant as it targets difficult-to-treat cancers with limited options.
Study Overview: Jazz Pharmaceuticals is conducting an observational study titled Observational Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy. The study aims to assess the risk of pregnancy and maternal complications, as well as other events of interest, on the developing fetus, neonate, and infant up to 12 months of life. This research is significant as it seeks to provide crucial insights into the safety of Epidiolex/Epidyolex during pregnancy.
Jazz Pharmaceuticals is conducting a study titled ‘Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox- Gastaut Syndrome (LGS), Dravet Syndrome (DS) and Tuberous Sclerosis Complex (TSC)’. The study aims to observe the effects of Epidyolex® on seizures in patients with LGS, DS, and TSC in Italy, highlighting its potential to improve patient outcomes in these challenging conditions.
Jazz Pharmaceuticals is conducting a Phase 3 study titled A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician’s Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer. The study aims to evaluate the effectiveness and safety of zanidatamab combined with chemotherapy compared to trastuzumab with chemotherapy in patients with metastatic HER2-positive breast cancer who have not responded to previous treatments. This study is significant as it explores new treatment options for a challenging cancer type.
Jazz Pharmaceuticals is currently conducting a clinical study titled ‘An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer.’ The study aims to evaluate the effectiveness and safety of Zanidatamab, in combination with Cisplatin and Gemcitabine, with or without a PD-1/L1 inhibitor, as a first-line treatment for HER2-positive biliary tract cancer. This study holds significant potential for improving treatment options for this aggressive cancer type.
Jazz Pharmaceuticals is conducting a study titled An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. The study aims to evaluate the efficacy and safety of Zanidatamab combined with CisGem (Cisplatin and Gemcitabine) and possibly a PD-1/L1 inhibitor, compared to standard care alone, for treating advanced HER2-positive biliary tract cancer.
Jazz Pharmaceuticals is conducting a pivotal study titled ‘An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer.’ The study aims to evaluate the effectiveness and safety of Zanidatamab combined with standard treatments, including Cisplatin and Gemcitabine, with or without a PD-1/L1 inhibitor, for patients with advanced HER2-positive biliary tract cancer. This research is significant as it could offer a new first-line treatment option for this challenging cancer type.